Wells Fargo Securities, LLC served as exclusive financial advisor to Ash Stevens, with legal counsel provided by Morrison & Foerster LLP as well as Honigman Miller Schwartz and Cohn LLP.
About Ash Stevens, Inc.
Ash Stevens, Inc. is a full service pharmaceutical Contract Manufacturing Organization (CMO) offering comprehensive small-molecule drug substance development and cGMP manufacturing services. Founded in 1962 and headquartered in Riverview, Michigan, Ash Stevens has extensive experience developing and manufacturing Active Pharmaceutical Ingredients (APIs) for Life Science companies developing innovator small-molecule therapeutics. Ash Stevens is a long-time provider of contract research services to the National Institutes of Health and the National Cancer Institute, and has participated in the development of many important drugs through these government agencies. To date, Ash Stevens has received fourteen FDA manufacturing approvals for innovator APIs, including a number of fast-track manufacturing approvals for the active ingredients for the oncology drugs Velcade®, Vidaza®, Clolar® and Iclusig®. Services offered by Ash Stevens include process development and scale-up; cGMP manufacturing; development and cGMP manufacture of highly potent APIs using barrier-isolation technology; comprehensive analytical capabilities (including method development, stability studies and qualification of reference standards); and regulatory support for all phases of drug development and manufacturing.
For more information, visit www.ashstevens.com or contact Dr. Stephen Munk, CEO (email@example.com).
Logo - http://photos.prnewswire.com/prnh/20150127/171655LOGO
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/piramal-pharma-solutions-announces-the-intent-to-acquire-ash-stevens-300314110.html
SOURCE Ash Stevens, Inc.